The COMPASS study (Cardiovascular Outcomes for People Using Anticoagulation Strategies) at the McMaster University has found that a protection with the combination of aspirin and rivaroxaban (drugs) is superior when compared with aspirin alone in individuals with the vascular disease.
The total number of participants in the study are 27,395 patients with stable atherosclerotic vascular disease from 33 countries. The study was intended to find out the superior protection between the rivaroxaban and the combination of rivaroxaban and aspirin to prevent stroke, heart attack and death.
Researchers in the study has compared the treatments between rivaroxaban (2.5 mg twice daily) combined with aspirin (100 mg once daily) and rivaroxaban (5 mg twice daily) or aspirin (100 mg once daily).
The study has found the combination of drugs can improve the stable coronary artery disease (or peripheral artery disease. PAD) and can increase the chances of a major bleeding (mainly in the gastroenterological).
The study also shows the protection with the drug combination is superior to aspirin in lowering the risk of limitation of blood flow to a limb (or damage to limbs) in patients of peripheral artery disease (PAD).
The aspirin can reduce the risk of major cardiovascular diseases by 19 percent. But a treatment with the combination of rivaroxaban and aspirin can reduce.
The lead author of the study was Dr. John W. Eikelboom, Associate Professor, Hematology & Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
The study was published on November 10, 2017, in The Lancet. Title of the article was "Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial."
A study has found a big increase in the number of young men and women patients of coronary artery diseases. Most of them are without risk factors for heart diseases such as hypertension (high blood pressure. BP), high blood sugar (glucose) levels (diabetes), high cholesterol levels, obesity (or higher body mass index. BMI ) and tobacco use.
Experts have reviewed the records of 695 patients of the heart attack at the Royal North Shore Hospital, St Leonards, Sydney, Australia, between 2006 and 2014. The researchers have found that 132 individuals are with heart diseases but without risk factors for heart diseases. The study has found an increase in heart diseases in young men and women from 11 percent in 2006 to 27 percent in 2014.
But the researchers could not able to identify the causes for the life-threatening coronary artery disease (plaque build up in the arteries or the development of atherosclerosis) in people without risk factors for heart diseases.
This study was funded by the University of Sydney and the Heart Research Australia. Senior author of the study was Dr. Gemma Figtree, Professor in Medicine, the University of Sydney and an interventional cardiologist at the Royal North Shore Hospital, (a public teaching hospital) at St Leonards, Sydney, Australia.
The study was published on July 13, 2017, in the European Journal of Preventive Cardiology. Title of the article was "Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.